Francisco Javier Melgosa Ramos

Dr. Francisco Javier Melgosa Ramos

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
NPNidia Planella-Fontanillas
Nidia Planella-Fontanillas
XBXavier Bosch-Amate
Xavier Bosch-Amate
AAAlicia Jiménez Antón
Alicia Jiménez Antón
CMCarlos Moreno-Vílchez
Carlos Moreno-Vílchez
MGMaría Gamo Guerrero
María Gamo Guerrero
LCLaia Curto-Barredo
Laia Curto-Barredo
Background: Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable. Objectives: Evaluate the effectiveness and safety of dupilumab in the treatment of BP. Methods: A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97.1%) received an initial 600-mg dose followed by 300 mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator’s Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed. Results: The study included 103 patients with a median age of 77.3 years; 58.3% were male. CR was achieved by 53.4% within 4 weeks and 95.7% by week 52. The PP-NRS score reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments. Conclusions: Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes.

15 March 2023 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
FRFrancisco Javier Melgosa Ramos
Francisco Javier Melgosa Ramos
RGR. García-Ruiz
R. García-Ruiz
APA. Mateu Puchades
A. Mateu Puchades
AMA. Martorell
A. Martorell

29 October 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FRFrancisco Javier Melgosa Ramos
Francisco Javier Melgosa Ramos
RRRamón García Ruiz
Ramón García Ruiz
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
APAlmudena Mateu Puchades
Almudena Mateu Puchades

24 September 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
FRFrancisco Javier Melgosa Ramos
Francisco Javier Melgosa Ramos
VGVíctor González‐Delgado
Víctor González‐Delgado
JMJosé María Sánchez Motilla
José María Sánchez Motilla
GMGalarreta Pascual Marta
Galarreta Pascual Marta
APAlmudena Mateu Puchades
Almudena Mateu Puchades
SSSantos Alarcón Sergio
Santos Alarcón Sergio

15 December 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
FRFrancisco Javier Melgosa Ramos
Francisco Javier Melgosa Ramos
RRRamón García Ruiz
Ramón García Ruiz
APAlmudena Mateu Puchades
Almudena Mateu Puchades

13 May 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
FRFrancisco Javier Melgosa Ramos
Francisco Javier Melgosa Ramos
RRRamón García Ruiz
Ramón García Ruiz
APAlmudena Mateu Puchades
Almudena Mateu Puchades
FRFernando Alfageme Roldán
Fernando Alfageme Roldán